Tebchaws Meskas Tuaj Tebchaws, Tebchaws Thoob Plaws Hauv Tebchaws Asmeskas, Lub Tebchaws Thoob Plaws Tebchaws Thoob Plaws Tebchaws

Fosaprepitant dimeglumine (EMEND) hmoov

Rating:
5.00 tawm ntawm 5 raws li nyob rau 1 neeg ntsuam xyuas
SKU: 265121-04-8. Qeb:

AASraw yog nrog synthesis thiab muaj peev xwm ua tau los ntawm cov gram kom huab hwm coj ntawm Fosaprepitant dimeglumine (EMEND) hmoov (265121-04-8), raws li CGMP kev tswj thiab kev tswj xyuas qhov system.

Fosaprepitant Dimeglumine hmoov yog lub dimeglumine ntsev ntawm fosaprepitant, dej-soluble, N-phosphorylated prodrug ntawm aprepitant, nrog antiemetic kev ua. Thaum tso cai rau intravenous thiab hloov ceev ceev mus rau aprepitant, tus neeg saib xyuas no khi ua rau tib neeg quav tshuaj P / neurokinin 1 (NK1) receptors nyob hauv nruab nrab lub paj hlwb (CNS). Qhov no inhibits receptor ruaj txog cov khoom tshuaj endogenous P thiab tiv thaiv cov khoom P-vim raug tshem tawm.

Hauj lwm yam khoom

Fosaprepitant dimeglumine (EMEND) hmoov video


Fosaprepitant dimeglumine (EMEND) hmoov theem pib

Lub npe: Fosaprepitant dimeglumine (EMEND) hmoov
CAS: 265121-04-8
Molecular Formula: C23H22F7N4O6P.2C7H17NO5
Molecular phaus: 1004.83
Melt Point: 242-247 ° C
Cia Temp: -20 ° C Freezer
xim: dawb mus rau dawb-dawb amorphous hmoov


Fosaprepitant dimeglumine (EMEND) Hmoov siv

lub npe

Fosaprepitant dimeglumine hmoov (CAS 265121-04-8)

EMEND hmoov

Fosaprepitant dimeglumine Hmoov siv

Ua ke nrog lwm cov tshuaj tiv thaiv cov tshuaj tiv thaiv, rau kev tiv thaiv ntawm mob qog thiab qaug zog thiab ntuav nrog thawj zaug thiab rov kawm cov kab mob qog nqaij hlav cancer hauv siab thiab mob nyhav loj kawg nkaus, nrog rau cov tshuaj uas muaj high-dose cisplatin.

Ceeb toom rau EMEND hmoov (CAS 265121-04-8)

  • Fosaprepitant yuav tsum siv ceev faj rau cov neeg mob uas tau txais cov tshuaj noj uas feem ntau metabolized los ntawm CYP3A4.
  • Cov tshuaj tiv thaiv kab mob sai sai no yuav tshwm sim thaum kis tas. Cov neeg mob muaj feem xyuam rau kev txiav kev poob haujlwm. Nws tsis pom zoo kom rov ua dua qhov Infusion. (B)
  • Kev tswj fosaprepitant los yog aprepitant nrog warfarin (ib tug CYP2C9 substrate) yuav ua rau kev txo qis hauv clinic International Standardized Ratio (INR) ntawm lub sij hawm prothrombin. (C)
  • Kev siv tshuaj ntawm hormonal contraceptives thaum lub caij nyoog thiab rau 28 hnub tom qab qhov kawg ntawm kev siv phosphate lossis aprepitant yuav txo. Lwm txoj kev los yog rov qab tu kev tiv thaiv yuav tsum raug siv. (D)

A: CYP3A4 Cov Kev Sib Tshuam Fosaprepitant tau hloov ceev ceev mus rau qhov chaw ua hauj lwm, uas yog lub cev tsis muaj zog ntawm CYP3A4 thaum ua raws li 3-hnub antiemetic dosing regimen rau CINV. Fosaprepitant yuav tsum siv ceev faj rau cov neeg mob uas tau txais cov tshuaj noj uas feem ntau metabolized los ntawm CYP3A4. Kev tiv thaiv ntawm CYP3A4 los ntawm aprepitant los yog fosaprepitant yuav ua rau cov ntshav siab ntau ntawm cov tshuaj no ua ke. Thaum fosaprepitant siv sib txuas nrog lwm tus kab mob CYP3A4 inhibitor, cov ntshav qab ntsev ntau yuav ua kom siab dua. Thaum aprepitant siv sib thooj nrog cov tshuaj uas ua rau CYP3A4 kev ua si, kev siv cov plasma concentrations yuav raug txo, thiab qhov no yuav ua rau muaj kev cuam tshuam tsawg ntawm aprepitant. Cov tshuaj tua kab mob uas paub tias yog metabolized los ntawm CYP3A4 muaj xws li docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine thiab vincristine. Hauv kev tshawb fawb soj ntsuam, qhov kev siv qhov ncauj ntawm qhov ncauj tau siv ntau yam nrog etoposide, vinorelbine, lossis paclitaxel. Cov koob tshuaj ntawm cov neeg ua hauj lwm no tsis raug kho rau cov txiaj ntsim ntawm kev siv tshuaj tua kab mob. Hauv cov kev tshawb fawb pharmacokinetic cais, tsis muaj kev hloov pauv hauv docetaxel los yog vinorelbine pharmacokinetics tau pom thaum lub qhov ncauj ntawm lub qhov ncauj khov kho. Vim muaj tsawg tus neeg mob hauv cov kev tshawb fawb soj ntsuam uas tau txais CYP3A4 substrates vinblastine, vincristine, los yog ifosfamide, kev ceev faj thiab ceev faj soj ntsuam raug qhia rau cov neeg mob uas tau txais cov neeg ua hauj lwm los yog lwm cov tshuaj tua kab mob metabolised feem ntau los ntawm CYP3A4 uas tsis tau kawm.
B: Cov Kev Tiv Thaiv Kab Mob Siab Cuam Tshuam Cov kev ceeb toom ntawm kev sib tshuam siab heev tam sim no xws li ntub, erythema, dyspnea, thiab anaphylaxis tau tshwm sim thaum lub sijhawm infusion ntawm fosaprepitant. Cov kev sib haum xeeb ntawm kev sib haum xeeb no feem ntau tau teb rau kev cuam tshuam ntawm Txoj Kev Mob Txoj Kev Mob thiab kev tswj kev tsim nyog kho. Kev rov ua dua ntawm Txoj Kev Mob Txoj Cai tsis pom zoo rau cov neeg mob uas muaj cov tsos mob no thaum siv thawj zaug.
C: Kev tswjfwm nrog Warfarin Kev tswj fwm ntawm fosaprepitant los yog aprepitant nrog warfarin tej zaum yuav ua rau kev txo qis qis hauv International Standardized Ratio (INR) ntawm prothrombin lub sijhawm. Hauv cov neeg mob ntawm cov kev kho mob ntawm cov tshuaj warfarin tsis ntev los no, tus INR yuav tsum tau zoo saib xyuas hauv 2 lub lim tiam, tshwj xeeb tshaj yog tom 7 rau 10 hnub, tom qab pib ntawm fosaprepitant nrog txhua lub chaw khomob.
D. Kev tswj hwm nrog Hormonal Contraceptives Raws li kev tswj fwm nrog phev phais lossis phais, qhov ua tau ntawm cov tshuaj hormonal contraceptives yuav raug txo kom tsawg lub sij hawm thiab rau 28 hnub tom qab qhov kawg ntawm kev phosaprepitant los yog aprepitant. Lwm txoj kev los sis rov qab tu cov tshuaj tiv thaiv kab mob yuav tsum tau siv rau thaum lub caij kho thiab nrog rau 1 lub hlis tom qab hnub kawg ntawm kev noj tshuaj los yog kev saib xyuas qhov chaw [saib cov yeeb tshuaj]. 5.5 Mob Nruam Kev Siv Nruam Kev Siv Nruam Kev siv tshuaj tiv thaiv EMEND hmoov rau Txhaj tshuaj tiv thaiv kev xeev siab thiab ntuav tsis pom zoo vim tias nws tsis tau kawm; thiab vim tias yeeb yaj duab kev sib txuas lus yuav hloov thaum siv kev siv tas mus li.

Cov lus qhia ntxiv

Fosaprepitant dimeglumine hmoov rau kev txhaj tshuaj 150 mg tam sim no tau qhia rau cov neeg laus nrog lwm cov tshuaj tiv thaiv cov tshuaj tiv thaiv rau kev tiv thaiv ntawm qaug zog thiab ntuav nrog thawj zaug thiab rov kawm dua ntawm MEC. Qhov kev pom zoo ntawm cov neeg laus yog ib zaug 150-mg tso dej kom ntws dhau 20 rau 30 feeb li kwv yees 30 ua ntej kws kho mob hauv Hnub 1. Kev pom zoo los ntawm FDA tshiab ntawm qhov kev qhia tshiab no yog nyob rau ntawm qhov kev tshawb pom ntawm randomized, parallel, doubleblind, kev sib piv ntawm tus sib piv sib txuas tshuaj uas soj ntsuam fosaprepitant rau kev txhaj tshuaj raws li ib qho kev txhaj tshuaj tua kab mob nrog rau ondansetron thiab dexamethasone (raug xa mus rau EMEND hmoov regimen ) (N = 502) piv nrog ondansetron thiab dexamethasone ib leeg (tswj kev tswj hwm) (N = 498) rau cov neeg mob uas tau txais MEC. Lub hauv paus xaus yog qhov kev teb tiav (txhais tias tsis muaj ntuav thiab tsis siv kev cawm txoj kev kho) nyob rau ncua sijhawm (25 mus rau 120 teev tom qab pib ntawm chemotherapy) ntawm kws kho mob siab vim ntuav thiab ntuav. Ib qho 78.9% teb cov lus teb tiav tau pom nrog lub Fosaprepitant dimeglumine hmoov regimen piv rau 68.5% nrog rau kev tswj kev tswj (P <0.001). Cov tshuaj tiv thaiv ntau tshaj tawm hauv EMEND hmoov regimen tiv thaiv tswj regimen muaj qaug zog (15% vs 13%), raws plab (13% vs 11%), neutropenia (8% vs 7%), asthenia (4% vs 3%) (3% vs 2%), peripheral neuropathy (3% vs 2%), leukopenia (2% vs 1%), dyspepsia (2% vs 1%), qhov mob txeeb zig (2% vs 1%), thiab mob hauv extremity (2% vs 1%).

Ntsuas Fosaprepitant Dimeglumine hmoov rau kev txhaj tshuaj, nrog rau lwm cov tshuaj tiv thaiv, yog qhia rau cov laus rau kev tiv thaiv ntawm mob qog thiab qaug zog thiab ntuav nrog pib thiab rov kawm cov kabmob kheesxaws siab heev, nrog rau ntau cov tshuaj cisplatin; thiab rau kev tiv thaiv ntawm qaug zog thiab ntuav nrog pib thiab rov kawm cov kab mob khees-xaws tshwjxeeb mob cancer hauv nroog nruab nrab.

Fosaprepitant dimeglumine hmoov rau kev txhaj tshuaj tsis tau kawm txog kev kho mob ntawm xeev siab thiab ntuav.

Fosaprepitant dimeglumine Raw Hmoov (CAS 265121-04-8)

Min yuam 10grams.
Cov lus nug txog ntawm ntau npaum li cas (Hauv 1kg) tuaj yeem xa tawm hauv 12 teev tom qab them nyiaj.
Rau kev loj dua (Hauv 1kg) tuaj yeem xa tawm hauv 3 hnub ua hauj lwm tom qab them nyiaj.

Fosaprepitant dimeglumine hmoov li

Kom muab rau yav tom ntej tom ntej.


Yuav ua li cas yuav Fosaprepitant dimeglumine hmoov: muas EMEND hmoov los ntawm AASraw

1.To tiv tauj peb ntawm peb tus email nug qhov system, lossis hauv internettus sawv cev rau tus neeg sawv cev (CSR).
2.To muab peb nug koj qhov ntau thiab qhov chaw nyob.
3.Our CSR yuav muab nqe lus hais txog koj, qhov them nqi, tus lej nrhiav, kev xaib thiab kwv yees hnub uas tuaj txog (ETA).
4.Payment ua tiav thiab cov khoom xa tuaj rau 12 cov xuab moos (Rau kev txiav txim hauv 10kg).
5.Goods tau txais thiab muab tswv yim.

PRECAUTION THIAB DISCLAIMER:

Cov Khoom Siv No Yog Muag Rau Kev Tshawb Xyuas Siv Xwb. Cov ntsiab lus ntawm kev muag khoom Thov. Tsis Yog Rau Tib Neeg Noj, Tsis Kho Mob, Kho Tsiaj, lossis Tsev Neeg Siv.


COA

COA 265121-04-8 Fosaprepitant dimeglumine (EMEND) hmoov AASRAW

HNMR

Peb yog Fosaprepitant dimeglumine hmoov tshuaj, EMEND hmoov rau muag, Fosaprepitant dimeglumine (EMEND) hmoov (265121-04-8) ≥98% | AASraw

Zaub mov txawv

Fosaprepitant dimeglumine Raw Pluas Noj Zaub:

Yog xav paub txog peb Tus Neeg Sawv Cev Kev Nkag Siab (CSR) kom paub meej, rau qhov koj siv.

References & cov khoom citations

Fosaprepitant Dimeglumine siv tshuaj tua kab mob cancer